AVAH (65) ADUS (69) WGS (58) OPCH (75) ⌘ Pro Terminal →

Privia Health Group Inc. (PRVA) — RQD Stock Rating Cockpit

$22.00 +0.71% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $21.99

Privia Health Group Inc. (PRVA) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $2.81B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $21.99 (-0.06%)🧬 Cannibal Buyback (-0.68% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 4.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-0.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRVA)Realized 20D OHLCV Swing Band: ±6%

Deterministic 5-Pillar Attribution (57/100 Composite)

🔍 WHY PRVA SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+14/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 4.1% FCF Margin ($163.4M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$20.85+8% Next Q

Q2 (-2Q)

Grade C-$22.52-0.5% Next Q

Q3 (-1Q)

Grade C-$22.41-1.8% Next Q

Current

Grade D+$22.00-0.2% Hist 90D α

Trajectory: D (49) → D+ (57)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PRVA Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, PRVA faces multiple-compression risk if 122.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Priced at 123x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($20.88) or 200D SMA ($22.67) invalidates the momentum regime and cuts Target Base ($21.90) toward Bear Floor ($17.08).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRVA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PRVA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 57%NO 43%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

48.930 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

6 / 99-Pt Accounting

52-WEEK LASER RANGE31% OF RANGE

L: $19$22.00H: $29

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: B-RQD 14 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on PRVA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (70)

10.5% ROIC with 42.0% gross margin and 5.82% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (50)

18/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like PRVA

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Priced at 123x earnings—high expectations leave less room for a lukewarm quarter.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRVA)

✓Walkthrough of PRVA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRVA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.47%⚡ TESTING RESISTANCE

2026-10-30O $22.10H $22.10L $21.30C $22.00VOL 841.2K

RES: $22.54SUP: $18.32SMA50: $20.88SMA200: $22.67

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRVA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRVA Butterfly Map → + Track PRVA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRVA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRVA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRVA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRVA)

Health Care Rank #250 of 1016 ⚔️ AVAH vs PRVA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRVA vs. AVAH, ADUS, WGS, OPCH)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Privia Health Group Inc. (PRVA) ranks #250 by composite RQD confidence (57/100, grade D+) and #214 by equity capitalization ($2.81B). Within this direct 5-issuer industry benchmark cohort, OPCH leads on earnings valuation at 23.0x trailing P/E, while AVAH leads on capital efficiency and profitability with 15.7% ROIC and 33.3% gross margin. OPCH currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with PRVA at 57/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRVA ACTIVE Privia Health Group Inc.	D+	57/100	122.6x	—	10.5%	+0.71%	$2.81B	Benchmark Subject
AVAH Aveanna Healthcare Holdings Inc.	C	65/100	—	33.3%	15.7%	+1.53%	$2.89B	/avah-vs-prva →
ADUS Addus HomeCare Corporation	C+	69/100	24.2x	32.5%	9.1%	+1.77%	$2.32B	/adus-vs-prva →
WGS GeneDx Holdings Corp. (Class A)	D+	58/100	—	69.7%	-4.1%	+9.79%	$2.12B	/wgs-vs-prva →
OPCH Option Care Health Inc.	B	75/100	23.0x	19.3%	11.9%	+1.79%	$4.77B	/opch-vs-prva →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001759655

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Privia Health Group Inc. (PRVA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $22.9M, operating cash flow of $163.4M, and free cash flow of $163.4M (+49.5% YoY). On the balance sheet, PRVA closed FY2025 with $1.37B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$22.9M	$163.4M	$163.4M	$1.37B	—
FY2024 (FY)	2024-12-31	$0	$14.4M	$109.3M	$109.3M	$1.14B	—
FY2023 (FY)	2023-12-31	$0	$23.1M	$80.8M	$80.8M	—	—

3. PRVA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Privia Health Group Inc. (NASDAQ: PRVA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $22.00 (+0.71% 1D, market cap $2.81B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, PRVA ranks #250 in composite RQD confidence.

How does PRVA compare to AVAH and ADUS in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), PRVA carries a Roarable D+ (57/100 RQD), trailing P/E of 122.6x, gross margin of —, and ROIC of 10.5%. By comparison, AVAH (Aveanna Healthcare Holdings Inc.) holds a C grade (65/100 RQD, P/E N/A, ROIC 15.7%, cap $2.89B) and ADUS (Addus HomeCare Corporation) posts a C+ grade (69/100 RQD, P/E 24.2x, ROIC 9.1%, cap $2.32B). Among the 5-stock peer group, OPCH leads on earnings multiple (23.0x) while AVAH leads on capital efficiency (15.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRVA?

Per PRVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001759655), Privia Health Group Inc. generated $0 in revenue, $22.9M in net income, and $163.4M in free cash flow against $1.37B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRVA trading relative to its 50-day, 200-day, and 52-week technical levels?

PRVA last traded at $22.00 (+0.71% on volume of 869,002 shares), positioning the stock +5.36% above its 50-day simple moving average ($20.88) and -2.96% below its 200-day simple moving average ($22.67). Across its 52-week range of $18.92 to $28.82, PRVA sits at the 31.1% percentile with a 14-day RSI of 48.9 (NEUTRAL RANGE) and an implied next-earnings move of ±6.0% ($20.68 to $23.32).

PRVA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PRVA stock right now?

Privia Health Group Inc. (PRVA) currently earns a Roarable Rating of D+ (Sell — SELL) with 57/100 RQD Confidence. Stretched risk/reward at 123x P/E (11% return on capital) under elevated 10-year interest-rate pressure.

What is PRVA's 12-month price target and RQD AI Jury consensus?

PRVA's 12-month base price target is $21.9 (range $17.08 to $30.26), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PRVA RQD Cockpit PRVA 12M Forecast PRVA Earnings & Move PRVA Dividends & DRIP PRVA Insiders & 13F PRVA Whale Options PRVA Profit Sankey PRVA News & Why